Liver cancer is one of the most challenging malignancies, often associated with poor prognosis and limited treatment options. Recent advancements in nanotechnology and artificial intelligence (AI) have opened new frontiers in the fight against this disease. Nanotechnology enables precise, targeted drug delivery, enhancing the efficacy of therapeutics while minimizing off-target effects. Simultaneously, AI contributes to improved diagnostic accuracy, predictive modeling, and the development of personalized treatment strategies. This review explores the convergence of nanotechnology and AI in liver cancer treatment, evaluating current progress, identifying existing research gaps, and discussing future directions. We highlight how AI-powered algorithms can optimize nanocarrier design, facilitate real-time monitoring of treatment efficacy, and enhance clinical decision-making. By integrating AI with nanotechnology, clinicians can achieve more accurate patient stratification and treatment personalization, ultimately improving patient outcomes. This convergence holds significant promise for transforming liver cancer therapy into a more precise, individualized, and efficient process. However, data privacy, regulatory hurdles, and the need for large-scale clinical validation remain. Addressing these issues will be essential to fully realizing the potential of these technologies in oncology.

Hepatocellular carcinoma is the fifth leading cancer in related diseases most commonly in men and women. The curative treatments of liver cancer are short-listed, associated with toxicities and therapeutically. Emerging nanotechnologies exhibited the possibility to treat or target liver cancer. Over the years, to phytosome solid lipid nanoparticles, gold, silver, liposomes, and phospholipid nanoparticles have been produced for liver cancer therapy, and some evidence of their effectiveness has been established. Ideas are limited to the laboratory scale, and in order to develop active targeting of nanomedicine for the clinical aspects, they must be extended to a larger scale. Thus, the current review focuses on previously and presently published research on the creation of phytosomal nanocarriers for the treatment of hepatocellular carcinoma. In hepatocellular carcinoma (HCC), phytosomal nanotherapeutics improve the targeted delivery and bioavailability of phytochemicals to tumor cells, thereby reducing systemic toxicity and increasing therapeutic efficacy. In order to address the intricate molecular processes implicated in HCC, this strategy is essential.

Unleashing the potential of phytosomal nanoparticles in brain tumor therapy. This article discusses the transforming potential of phytosomal nanoparticles in the fight against brain tumors, delving into this novel field. When the complex problems of traditional medicine are considered, the special qualities of phytosomal nanoparticles show great potential. Because of the nanoparticles’ ability to cross the blood-brain barrier, it is possible to transport drugs specifically to the brain, which solves a long-standing issue with current treatments. This accuracy reduces off-target effects, providing a crucial therapeutic benefit in a sensitive brain environment. Phytosomal formulations are further distinguished by their lower toxicity and biocompatibility, which establishes them as a safer substitute for several traditional medicines. These natural compound-based nanoparticles fit in with the medical paradigm shift towards personalized and integrative care. The versatility of phytosomal formulations opens up new avenues for personalized medicine in the treatment of brain tumors by enabling customized approaches based on the molecular profiles of individual tumors.Phytosomal nanoparticles provide a unique combination of natural pharmacopeia and state-of-the-art nanotechnology, which presents opportunities for novel therapeutic approaches beyond their clinical usefulness. The consequences could change the way brain tumors are treated as research and clinical trials are conducted. In order to overcome obstacles related to scalability, legal frameworks, and long-term safety assessments, cooperation between researchers, physicians, and legislators is essential. The full potential of phytosomal nanoparticles in the fight against brain tumors will be realized through ongoing research into how they might work in concert with current therapies and the creation of evidence-based guidelines. This article essentially presents a paradigm shift that will have a significant impact on cancer therapy in the future. It is the result of the convergence of innovative ideas inspired by nature with state-of-the-art nanotechnology.

The Asian Journal of Pharmaceutics is a peer-reviewed open-access medical journal published by Medknow Publications on behalf of the B.R. Nahata Smriti Sansthan (Memorial Trust) (Mandsaur, India). Articles address topics in pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, and clinical and hospital pharmacy.